I 
110TH CONGRESS 
2D SESSION 
H. R. 5629 
To amend the Public Health Service Act to establish a pathway for the 
licensure of biosimilar biological products, and for other purposes. 
IN THE HOUSE OF REPRESENTATIVES 
MARCH 13, 2008 
Ms. ESHOO (for herself, Mr. BARTON of Texas, Mr. HILL, Mr. UPTON, Mr. 
WYNN, Mr. PITTS, Ms. ZOE LOFGREN of California, Mr. ROGERS of 
Michigan, Mr. CAPUANO, Mr. BUYER, Mr. MCGOVERN, Mr. TIM MURPHY 
of Pennsylvania, Mr. LYNCH, and Mr. FERGUSON) introduced the fol-
lowing bill; which was referred to the Committee on Energy and Com-
merce, and in addition to the Committee on the Judiciary, for a period 
to be subsequently determined by the Speaker, in each case for consider-
ation of such provisions as fall within the jurisdiction of the committee 
concerned 
A BILL 
To amend the Public Health Service Act to establish a path-
way for the licensure of biosimilar biological products, 
and for other purposes. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 1. SHORT TITLE. 
This Act may be cited as the ‘‘Pathway for 
Biosimilars Act’’. 
VerDate Aug 31 2005 
23:13 Mar 14, 2008
Jkt 069200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6201
E:\BILLS\H5629.IH
H5629
rwilkins on PROD1PC63 with BILLS
SEC. 2. TABLE OF CONTENTS. 
The table of contents for this Act is as follows: 
Sec. 1. Short title. 
Sec. 2. Table of contents. 
TITLE I—AMENDMENTS TO PUBLIC HEALTH SERVICE ACT 
Sec. 101. Approval pathway for biosimilar biological products. 
Sec. 102. Fees relating to biosimilar biological products. 
TITLE II—AMENDMENTS TO PATENT ACT 
Sec. 201. Amendments to certain patent provisions. 
TITLE I—AMENDMENTS TO 
PUBLIC HEALTH SERVICE ACT 
SEC. 101. LICENSURE PATHWAY FOR BIOSIMILAR BIOLOGI-
CAL PRODUCTS. 
(a) LICENSURE OF BIOLOGICAL PRODUCTS AS BIO-
SIMILAR
OR INTERCHANGEABLE.—Section 351 of the 
Public Health Service Act (42 U.S.C. 262) is amended— 
(1) in subsection (a)(1)(A), by inserting ‘‘under 
this subsection or subsection (k)’’ after ‘‘biologics li-
cense’’; and 
(2) by adding at the end the following: 
‘‘(k) LICENSURE OF BIOLOGICAL PRODUCTS AS BIO-
SIMILAR.— 
‘‘(1) IN GENERAL.—Any person may submit an 
application for licensure of a biological product 
under this subsection. 
‘‘(2) CONTENT.— 
VerDate Aug 31 2005 
23:13 Mar 14, 2008
Jkt 069200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6201
E:\BILLS\H5629.IH
H5629
rwilkins on PROD1PC63 with BILLS
‘‘(A) REQUIRED INFORMATION.—An appli-
cation submitted under this subsection shall in-
clude information demonstrating that— 
‘‘(i) the biological product is bio-
similar to a reference product based upon 
data derived from— 
‘‘(I) analytical studies that dem-
onstrate that the biological product is 
highly similar to the reference product 
notwithstanding minor differences in 
clinically inactive components; 
‘‘(II) animal studies (including 
the assessment of toxicity); and 
‘‘(III) a clinical study or studies 
(including, but not limited to, the as-
sessment of immunogenicity and phar-
macokinetics or pharmacodynamics) 
that are sufficient to demonstrate 
safety, purity, and potency for each 
condition of use for which the ref-
erence product is approved; 
‘‘(ii) the biological product and ref-
erence product utilize the same mechanism 
or mechanisms of action for the condition 
or conditions of use prescribed, rec-
VerDate Aug 31 2005 
23:13 Mar 14, 2008
Jkt 069200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6201
E:\BILLS\H5629.IH
H5629
rwilkins on PROD1PC63 with BILLS
ommended, or suggested in the proposed 
labeling, but only to the extent the mecha-
nism or mechanisms of action are known 
for the reference product; 
‘‘(iii) the condition or conditions of 
use prescribed, recommended, or suggested 
in the labeling proposed for the biological 
product have been previously approved for 
the reference product; 
‘‘(iv) the route of administration, the 
dosage form, and the strength of the bio-
logical product are the same as those of 
the reference product; and 
‘‘(v) the facility in which the biological 
product 
is 
manufactured, 
processed, 
packed, or held meets standards designed 
to assure that the biological product con-
tinues to be safe, pure, and potent. 
‘‘(B) WAIVER
REGARDING
ANALYTICAL 
STUDIES, 
ANIMAL
STUDIES, 
AND
CLINICAL 
STUDIES.— 
‘‘(i) IN
GENERAL.—The Secretary 
may, in the Secretary’s discretion, deter-
mine that an element described in sub-
clause (I), (II), or (III) of subparagraph 
VerDate Aug 31 2005 
23:13 Mar 14, 2008
Jkt 069200
PO 00000
Frm 00004
Fmt 6652
Sfmt 6201
E:\BILLS\H5629.IH
H5629
rwilkins on PROD1PC63 with BILLS
(A)(i) is unnecessary and waive the re-
quirement that such element be submitted 
in an application under this subsection. 
‘‘(ii) 
ASSESSMENTS
OF 
IMMUNOGENICITY.—Notwithstanding 
clause (i), the Secretary may determine 
that an assessment of immunogenity de-
scribed in subparagraph (A)(i)(III) is un-
necessary and waive the requirement that 
such an assessment be submitted in an ap-
plication under this subsection only if the 
Secretary has published a final guidance, 
following receipt and consideration of pub-
lic comments on a draft guidance— 
‘‘(I) advising that it is feasible in 
the current state of scientific knowl-
edge to make determinations on 
immunogenicity with respect to prod-
ucts in the product class to which the 
biological product belongs; and 
‘‘(II) explaining the data that 
will be required to support such a de-
termination. 
‘‘(C) ADDITIONAL INFORMATION.—An ap-
plication submitted under this subsection— 
VerDate Aug 31 2005 
02:49 Mar 15, 2008
Jkt 069200
PO 00000
Frm 00005
Fmt 6652
Sfmt 6201
E:\BILLS\H5629.IH
H5629
rwilkins on PROD1PC63 with BILLS
‘‘(i) shall include publicly-available in-
formation regarding the Secretary’s pre-
vious determination that the reference 
product is safe, pure, and potent; and 
‘‘(ii) may include any additional infor-
mation in support of the application, in-
cluding publicly-available information with 
respect to the reference product or another 
biological product. 
‘‘(3) EVALUATION BY SECRETARY.—Upon re-
view of an application (or a supplement to an appli-
cation) submitted under this subsection, the Sec-
retary shall approve the application (or the supple-
ment) if— 
‘‘(A) the Secretary determines that the in-
formation submitted in the application (or the 
supplement) is sufficient to show that the bio-
logical product is biosimilar to the reference 
product with respect to each condition of use 
for which the reference product is approved; 
and 
‘‘(B) the applicant (or other appropriate 
person) consents to the inspection of the facility 
that is the subject of the application, in accord-
ance with subsection (c). 
VerDate Aug 31 2005 
23:13 Mar 14, 2008
Jkt 069200
PO 00000
Frm 00006
Fmt 6652
Sfmt 6201
E:\BILLS\H5629.IH
H5629
rwilkins on PROD1PC63 with BILLS
‘‘(4) SAFETY
STANDARDS
FOR
DETERMINING 
INTERCHANGEABILITY.— 
‘‘(A) DETERMINATION.—Upon review of 
an application submitted under this subsection 
or any supplement to such application, the Sec-
retary shall determine the biological product to 
be interchangeable with the reference product if 
the Secretary determines that the information 
submitted in the application (or a supplement 
to such application) is sufficient to show that— 
‘‘(i) the biological product— 
‘‘(I) is biosimilar to the reference 
product and any biological product li-
censed under this subsection that has 
been determined to be interchangeable 
with the reference product; and 
‘‘(II) can be expected to produce 
the same clinical result as the ref-
erence product in any given patient 
for each condition of use prescribed, 
recommended, or suggested in the la-
beling of the reference product; and 
‘‘(ii) for a biological product that is 
administered more than once to an indi-
vidual, the risk in terms of safety or dimin-
VerDate Aug 31 2005 
23:13 Mar 14, 2008
Jkt 069200
PO 00000
Frm 00007
Fmt 6652
Sfmt 6201
E:\BILLS\H5629.IH
H5629
rwilkins on PROD1PC63 with BILLS
ished efficacy of alternating or switching 
between use of the biological product and 
the reference product is not greater than 
the risk of using the reference product 
without such alternation or switch. 
‘‘(B) GUIDELINES.—Notwithstanding sub-
paragraph (A), the Secretary may not make a 
determination that a biological product licensed 
under this subsection is interchangeable with 
the reference product unless the Secretary has 
published a final guidance, following receipt and 
consideration of public comments on a draft 
guidance— 
‘‘(i) advising that it is feasible in the 
current state of scientific knowledge to 
make such determinations with respect to 
products in the product class to which that 
biological product belongs; and 
‘‘(ii) explaining the data that will be 
required to support such a determination. 
‘‘(5) GENERAL RULES.— 
‘‘(A) ONE REFERENCE PRODUCT PER AP-
PLICATION.—A biological product, in an appli-
cation submitted under this subsection, may not 
VerDate Aug 31 2005 
23:13 Mar 14, 2008
Jkt 069200
PO 00000
Frm 00008
Fmt 6652
Sfmt 6201
E:\BILLS\H5629.IH
H5629
rwilkins on PROD1PC63 with BILLS
be evaluated against more than 1 reference 
product. 
‘‘(B) REVIEW.—An application submitted 
under this subsection shall be reviewed by the 
division within the Food and Drug Administra-
tion that is responsible for the review and ap-
proval of the application under which the ref-
erence product is licensed. 
‘‘(C) RISK EVALUATION AND MITIGATION 
STRATEGIES.—The authority of the Secretary 
with respect to risk evaluation and mitigation 
strategies under the Federal Food, Drug, and 
Cosmetic Act shall apply to biological products 
licensed under this subsection in the same man-
ner as such authority applies to biological prod-
ucts licensed under subsection (a). 
‘‘(D) LISTED SELECT AGENTS AND TOX-
INS.—If information in an application sub-
mitted under this subsection, in a supplement 
to such an application, or otherwise available to 
the Secretary shows that a biological product is, 
bears, or contains a select agent or toxin listed 
in section 73.3 or 73.4 of title 42, section 121.3 
or 121.4 of title 9, or section 331.3 of title 7 
of the Code of Federal Regulations (or any suc-
VerDate Aug 31 2005 
23:13 Mar 14, 2008
Jkt 069200
PO 00000
Frm 00009
Fmt 6652
Sfmt 6201
E:\BILLS\H5629.IH
H5629
rwilkins on PROD1PC63 with BILLS
cessor regulations), the Secretary shall not li-
cense the biological product under this sub-
section. 
‘‘(6) EXCLUSIVITY FOR FIRST INTERCHANGE-
ABLE BIOLOGICAL PRODUCT.—The Secretary shall 
not make a determination under paragraph (4) that 
a second or subsequent biological product is inter-
changeable with the same reference product for 
which a prior biological product has received a deter-
mination of interchangeability until 24 months after 
the later of— 
‘‘(A) the date of the first commercial mar-
keting of the first biosimilar biological product 
determined to be interchangeable for that ref-
erence product; or 
‘‘(B) with respect to a product marketed 
before the date the product is determined to be 
interchangeable, the date that the product is 
determined to be interchangeable. 
‘‘(7) EXCLUSIVITY
FOR
REFERENCE
PROD-
UCT.— 
‘‘(A) EFFECTIVE DATE OF BIOSIMILAR AP-
PLICATION
LICENSURE.—Subject to subpara-
graph (D) and paragraph (8), approval of an 
application under this subsection may not be 
VerDate Aug 31 2005 
23:13 Mar 14, 2008
Jkt 069200
PO 00000
Frm 00010
Fmt 6652
Sfmt 6201
E:\BILLS\H5629.IH
H5629
rwilkins on PROD1PC63 with BILLS
made effective by the Secretary until the date 
that is 12 years after the date on which the ref-
erence product was first licensed under sub-
section (a). 
‘‘(B) FILING
PERIOD.—An application 
under this subsection may not be submitted to 
the Secretary until the later of— 
‘‘(i) the date of commencement of a 
proceeding for issuance of guidance pursu-
ant to paragraph (9) with respect to the 
product class within which the product 
that is the subject of such application falls; 
or 
‘‘(ii) the date that is 4 years after the 
date on which the reference product was 
first licensed under subsection (a). 
‘‘(C) FIRST LICENSURE.—For purposes of 
this paragraph, the date on which the reference 
product was first licensed under subsection (a) 
does not include the date of approval of a sup-
plement or of a subsequent application for a 
new indication, route of administration, dosage 
form, or strength for the previously licensed ref-
erence product. 
VerDate Aug 31 2005 
23:13 Mar 14, 2008
Jkt 069200
PO 00000
Frm 00011
Fmt 6652
Sfmt 6201
E:\BILLS\H5629.IH
H5629
rwilkins on PROD1PC63 with BILLS
‘‘(D) MEDICALLY SIGNIFICANT NEW INDI-
CATION.—If, during the 8-year period following 
licensure of the reference product, the Secretary 
approves a supplement to the application for 
the reference product that seeks approval to 
market the reference product for a new indica-
tion that, if approved, would be a significant 
improvement, compared to marketed products, 
in the treatment, diagnosis, or prevention of 
disease, approval of an application submitted 
under this subsection may not be made effective 
by the Secretary until the date that is 14 years 
after the date on which the reference product 
was first licensed under subsection (a). 
‘‘(8) PEDIATRIC STUDIES.— 
‘‘(A) EXCLUSIVITY.—If, before or after li-
censure of the reference product under sub-
section (a) of this section, the Secretary deter-
mines that information relating to the use of 
such product in the pediatric population may 
produce health benefits in that population, the 
Secretary makes a written request for pediatric 
studies (which shall include a timeframe for 
completing such studies), the applicant or hold-
er of the approved application agrees to the re-
VerDate Aug 31 2005 
23:13 Mar 14, 2008
Jkt 069200
PO 00000
Frm 00012
Fmt 6652
Sfmt 6201
E:\BILLS\H5629.IH
H5629
rwilkins on PROD1PC63 with BILLS
quest, such studies are completed using appro-
priate formulations for each age group for 
which the study is requested within any such 
timeframe, and the reports thereof are sub-
mitted and accepted in accordance with section 
505A(d)(3) of the Federal Food, Drug, and 
Cosmetic Act— 
‘‘(i) the period referred to in para-
graph (7)(A) of this subsection is deemed 
to be 12 years and 6 months rather than 
12 years; and 
‘‘(ii) if paragraph (7)(D) of this sub-
section applies, the period referred to in 
such paragraph is deemed to be 14 years 
and 6 months rather than 14 years. 
‘‘(B) EXCEPTION.—The Secretary shall 
not extend the period referred to in subpara-
graph (A)(i) or (A)(ii) of this paragraph if the 
determination under section 505A(d)(3) of the 
Federal Food, Drug, and Cosmetic Act is made 
later than 9 months prior to the expiration of 
such period. 
‘‘(C) APPLICATION
OF
CERTAIN
PROVI-
SIONS.—The provisions of subsections (a), (d), 
(e), (f), (h), (j), (k), and (l) of section 505A of 
VerDate Aug 31 2005 
23:13 Mar 14, 2008
Jkt 069200
PO 00000
Frm 00013
Fmt 6652
Sfmt 6201
E:\BILLS\H5629.IH
H5629
rwilkins on PROD1PC63 with BILLS
the Federal Food, Drug, and Cosmetic Act 
shall apply with respect to the extension of a 
period under subparagraph (A) of this para-
graph to the same extent and in the same man-
ner as such provisions apply with respect to the 
extension of a period under subsection (b) or 
(c) of section 505A of the Federal Food, Drug, 
and Cosmetic Act. 
‘‘(9) GUIDANCE DOCUMENTS.— 
‘‘(A) IN GENERAL.—The Secretary shall, 
after opportunity for public comment, issue 
final guidance with respect to the licensure 
under this subsection of a biological product or 
product class. Such guidance shall be issued in 
accordance, except as provided in subparagraph 
(B)(i), with section 701(h) of the Federal Food, 
Drug, and Cosmetic Act. 
‘‘(B) PUBLIC COMMENT.— 
‘‘(i) IN
GENERAL.—Before issuing 
final guidance under subparagraph (A), 
the Secretary shall publish a proposed 
guidance, provide an opportunity for the 
public to comment on the proposed guid-
ance, and publish a response to comments 
received under this clause. 
VerDate Aug 31 2005 
23:13 Mar 14, 2008
Jkt 069200
PO 00000
Frm 00014
Fmt 6652
Sfmt 6201
E:\BILLS\H5629.IH
H5629
rwilkins on PROD1PC63 with BILLS
‘‘(ii) INPUT REGARDING MOST VALU-
ABLE GUIDANCE.—The Secretary shall es-
tablish a process through which the public 
may provide the Secretary with input re-
garding priorities for issuing guidance. 
‘‘(C) CERTAIN PRODUCT CLASSES.— 
‘‘(i) GUIDANCE.—The Secretary may 
indicate in a guidance document under 
subparagraph (A) that the Secretary will 
not license a product or product class (not 
including any recombinant protein) under 
this subsection because the science and ex-
perience, as of the date of such guidance, 
does not allow such licensure. 
‘‘(ii) MODIFICATION OR REVERSAL.— 
The Secretary may issue a subsequent 
guidance document under subparagraph 
(A) to modify or reverse a guidance docu-
ment under clause (i). 
‘‘(D) PETITION FOR INITIATION OF GUID-
ANCE FOR CERTAIN PRODUCTS.—In the case of 
a reference product that was licensed by the 
Secretary more than 7 years prior to the date 
of 
the 
enactment 
of 
the 
Pathway 
for 
Biosimilars Act, a person may petition the Sec-
VerDate Aug 31 2005 
23:13 Mar 14, 2008
Jkt 069200
PO 00000
Frm 00015
Fmt 6652
Sfmt 6201
E:\BILLS\H5629.IH
H5629
rwilkins on PROD1PC63 with BILLS
retary at any time to commence the process for 
issuing final guidance under subparagraph (A) 
for the product class to which the reference 
product belongs. Any such petition shall include 
a description of the scientific feasibility and ra-
tionale for the request. For guidance petitioned 
under this subparagraph, the Secretary shall, 
within 2 years of such petition, issue final guid-
ance with respect to that product class. 
‘‘(E) REQUIREMENT
FOR
APPLICATION 
CONSIDERATION.—The Secretary may not ac-
cept an application under this subsection until 
the Secretary has initiated a proceeding for 
issuance of guidance with respect to the product 
class within which the product that is the sub-
ject of the application falls. The Secretary may 
not approve an application under this sub-
section until the Secretary has completed the 
proceeding for issuance of guidance with re-
spect to the product class within which the 
product that is the subject of the application 
falls. 
‘‘(F) REQUIREMENT FOR PRODUCT CLASS- 
SPECIFIC
GUIDANCE.—Product 
class-specific 
VerDate Aug 31 2005 
23:13 Mar 14, 2008
Jkt 069200
PO 00000
Frm 00016
Fmt 6652
Sfmt 6201
E:\BILLS\H5629.IH
H5629
rwilkins on PROD1PC63 with BILLS
guidance issued under subparagraph (A) shall 
include a description of— 
‘‘(i) the criteria that the Secretary will 
use to determine whether a biological prod-
uct is biosimilar to a reference product in 
such product class; 
‘‘(ii) the criteria, if available, that the 
Secretary will use to determine whether a 
biological product meets the standards for 
interchangeability described in paragraph 
(4); and 
‘‘(iii) the criteria, if available, that the 
Secretary 
will 
use 
to 
assess 
immunogenicity. 
‘‘(10) NAMING.—The Secretary shall ensure 
that the labeling and packaging of each biological 
product licensed under this subsection bears a name 
that uniquely identifies the biological product and 
distinguishes it from the reference product and any 
other biological products licensed under this sub-
section following evaluation against such reference 
product. 
‘‘(l) PATENT NOTICES; RELATIONSHIP TO FINAL AP-
PROVAL.— 
VerDate Aug 31 2005 
23:13 Mar 14, 2008
Jkt 069200
PO 00000
Frm 00017
Fmt 6652
Sfmt 6201
E:\BILLS\H5629.IH
H5629
rwilkins on PROD1PC63 with BILLS
‘‘(1) DEFINITIONS.—For the purposes of this 
subsection, the term— 
‘‘(A) ‘biosimilar product’ means the bio-
logical product that is the subject of the appli-
cation under subsection (k); 
‘‘(B) ‘relevant patent’ means a patent 
that— 
‘‘(i) expires after the date specified in 
subsection (k)(7)(A) that applies to the 
reference product; and 
‘‘(ii) could reasonably be asserted 
against the applicant due to the unauthor-
ized making, use, sale, or offer for sale 
within the United States, or the importa-
tion into the United States of the bio-
similar product, or materials used in the 
manufacture of the biosimilar product, or 
due to a use of the biosimilar product in 
a method of treatment that is indicated in 
the application; 
‘‘(C) ‘reference product sponsor’ means the 
holder of an approved application or license for 
the reference product; and 
‘‘(D) ‘interested third party’ means a per-
son other than the reference product sponsor 
VerDate Aug 31 2005 
23:13 Mar 14, 2008
Jkt 069200
PO 00000
Frm 00018
Fmt 6652
Sfmt 6201
E:\BILLS\H5629.IH
H5629
rwilkins on PROD1PC63 with BILLS
that owns a relevant patent, or has the right to 
commence or participate in an action for in-
fringement of a relevant patent. 
‘‘(2) HANDLING OF CONFIDENTIAL INFORMA-
TION.—Any entity receiving confidential information 
pursuant to this subsection shall designate one or 
more individuals to receive such information. Each 
individual so designated shall execute an agreement 
in accordance with regulations promulgated by the 
Secretary. The regulations shall require each such 
individual to take reasonable steps to maintain the 
confidentiality of information received pursuant to 
this subsection and use the information solely for 
purposes authorized by this subsection. The obliga-
tions imposed on an individual who has received con-
fidential information pursuant to this subsection 
shall continue until the individual returns or de-
stroys the confidential information, a court imposes 
a protective order that governs the use or handling 
of the confidential information, or the party pro-
viding the confidential information agrees to other 
terms or conditions regarding the handling or use of 
the confidential information. 
‘‘(3) PUBLIC NOTICE BY SECRETARY.—Within 
30 days of acceptance by the Secretary of an appli-
VerDate Aug 31 2005 
23:13 Mar 14, 2008
Jkt 069200
PO 00000
Frm 00019
Fmt 6652
Sfmt 6201
E:\BILLS\H5629.IH
H5629
rwilkins on PROD1PC63 with BILLS
cation filed under subsection (k), the Secretary shall 
publish a notice identifying— 
‘‘(A) the reference product identified in the 
application; and 
‘‘(B) the name and address of an agent 
designated by the applicant to receive notices 
pursuant to paragraph (4)(B). 
‘‘(4) EXCHANGES CONCERNING PATENTS.— 
‘‘(A) 
EXCHANGES
WITH
REFERENCE 
PRODUCT SPONSOR.— 
‘‘(i) Within 30 days of the date of ac-
ceptance of the application by the Sec-
retary, the applicant shall provide the ref-
erence product sponsor with a copy of the 
application and information concerning the 
biosimilar product and its production. This 
information shall include a detailed de-
scription of the biosimilar product, its 
method of manufacture, and the materials 
used in the manufacture of the product. 
‘‘(ii) Within 60 days of the date of re-
ceipt of the information required to be pro-
vided under clause (i), the reference prod-
uct sponsor shall provide to the applicant 
a list of relevant patents owned by the ref-
VerDate Aug 31 2005 
23:13 Mar 14, 2008
Jkt 069200
PO 00000
Frm 00020
Fmt 6652
Sfmt 6201
E:\BILLS\H5629.IH
H5629
rwilkins on PROD1PC63 with BILLS
erence product sponsor, or in respect of 
which the reference product sponsor has 
the right to commence an action of in-
fringement or otherwise has an interest in 
the patent as such patent concerns the bio-
similar product. 
‘‘(iii) If the reference product sponsor 
is issued or acquires an interest in a rel-
evant patent after the date on which the 
reference product sponsor provides the list 
required by clause (ii) to the applicant, the 
reference product sponsor shall identify 
that patent to the applicant within 30 days 
of the date of issue of the patent, or the 
date of acquisition of the interest in the 
patent, as applicable. 
‘‘(B) 
EXCHANGES
WITH
INTERESTED 
THIRD PARTIES.— 
‘‘(i) At any time after the date on 
which the Secretary publishes a notice for 
an application under paragraph (3), any 
interested third party may provide notice 
to the designated agent of the applicant 
that the interested third party owns or has 
rights under 1 or more patents that may 
VerDate Aug 31 2005 
23:13 Mar 14, 2008
Jkt 069200
PO 00000
Frm 00021
Fmt 6652
Sfmt 6201
E:\BILLS\H5629.IH
H5629
rwilkins on PROD1PC63 with BILLS
be relevant patents. The notice shall iden-
tify at least 1 patent and shall designate 
an individual who has executed an agree-
ment in accordance with paragraph (2) to 
receive confidential information from the 
applicant. 
‘‘(ii) Within 30 days of the date of re-
ceiving notice pursuant to clause (i), the 
applicant shall send to the individual des-
ignated by the interested third party the 
information 
specified 
in 
subparagraph 
(A)(i), unless the applicant and interested 
third party otherwise agree. 
‘‘(iii) Within 90 days of the date of 
receiving information pursuant to clause 
(ii), the interested third party shall provide 
to the applicant a list of relevant patents 
which the interested third party owns, or 
in respect of which the interested third 
party has the right to commence or partici-
pate in an action for infringement. 
‘‘(iv) If the interested third party is 
issued or acquires an interest in a relevant 
patent after the date on which the inter-
ested third party provides the list required 
VerDate Aug 31 2005 
23:13 Mar 14, 2008
Jkt 069200
PO 00000
Frm 00022
Fmt 6652
Sfmt 6201
E:\BILLS\H5629.IH
H5629
rwilkins on PROD1PC63 with BILLS
by clause (iii), the interested third party 
shall identify that patent within 30 days of 
the date of issue of the patent, or the date 
of acquisition of the interest in the patent, 
as applicable. 
‘‘(C) IDENTIFICATION OF BASIS FOR IN-
FRINGEMENT.—For any patent identified under 
clause (ii) or (iii) of subparagraph (A) or under 
clause (iii) or (iv) of subparagraph (B), the ref-
erence product sponsor or the interested third 
party, as applicable— 
‘‘(i) shall explain in writing why the 
sponsor or the interested third party be-
lieves the relevant patent would be in-
fringed by the making, use, sale, or offer 
for sale within the United States, or im-
portation into the United States, of the 
biosimilar product or by a use of the bio-
similar product in treatment that is indi-
cated in the application; 
‘‘(ii) may specify whether the relevant 
patent is available for licensing; and 
‘‘(iii) shall specify the number and 
date of expiration of the relevant patent. 
VerDate Aug 31 2005 
23:13 Mar 14, 2008
Jkt 069200
PO 00000
Frm 00023
Fmt 6652
Sfmt 6201
E:\BILLS\H5629.IH
H5629
rwilkins on PROD1PC63 with BILLS
‘‘(D) CERTIFICATION BY APPLICANT CON-
CERNING
IDENTIFIED
RELEVANT
PATENTS.— 
Not later than 45 days after the date on which 
a patent is identified under clause (ii) or (iii) of 
subparagraph (A) or under clause (iii) or (iv) of 
subparagraph (B), the applicant shall send a 
written statement regarding each identified pat-
ent to the party that identified the patent. Such 
statement shall either— 
‘‘(i) state that the applicant will not 
commence marketing of the biosimilar 
product and has requested the Secretary to 
not grant final approval of the application 
before the date of expiration of the noticed 
patent; or 
‘‘(ii) provide a detailed written expla-
nation setting forth the reasons why the 
applicant believes— 
‘‘(I) the making, use, sale, or 
offer for sale within the United 
States, or the importation into the 
United States, of the biosimilar prod-
uct, or the use of the biosimilar prod-
uct in a treatment indicated in the ap-
VerDate Aug 31 2005 
23:13 Mar 14, 2008
Jkt 069200
PO 00000
Frm 00024
Fmt 6652
Sfmt 6201
E:\BILLS\H5629.IH
H5629
rwilkins on PROD1PC63 with BILLS
plication, would not infringe the pat-
ent; or 
‘‘(II) the patent is invalid or un-
enforceable. 
‘‘(5) ACTION
FOR
INFRINGEMENT
INVOLVING 
REFERENCE PRODUCT SPONSOR.—If an action for 
infringement concerning a relevant patent identified 
by the reference product sponsor under clause (ii) or 
(iii) of paragraph (4)(A), or by an interested third 
party under clause (iii) or (iv) of paragraph (4)(B), 
is brought within 60 days of the date of receipt of 
a statement under paragraph (4)(D)(ii), and the 
court in which such action has been commenced de-
termines the patent is infringed prior to the date ap-
plicable under subsection (k)(7)(A), (k)(7)(D), or 
(k)(8) the Secretary shall make approval of the ap-
plication effective on the day after the date of expi-
ration of the patent that has been found to be in-
fringed. If more than one such patent is found to be 
infringed by the court, the approval of the applica-
tion shall be made effective on the day after the date 
that the last such patent expires. 
‘‘(6) LIMITATIONS ON ACTIONS FOR DECLARA-
TORY JUDGMENT.—With respect to a patent that is 
the subject of an explanation under paragraph 
VerDate Aug 31 2005 
23:13 Mar 14, 2008
Jkt 069200
PO 00000
Frm 00025
Fmt 6652
Sfmt 6201
E:\BILLS\H5629.IH
H5629
rwilkins on PROD1PC63 with BILLS
(4)(D)(ii), no action for a declaratory judgment that 
the patent is invalid, unenforceable, or not infringed 
may be brought under section 2201 of title 28, 
United States Code, by an applicant prior to the 
date that is the later of— 
‘‘(A) 3 years prior to the date applicable 
under subsection (k)(7)(A); or 
‘‘(B) 120 days after such explanation has 
been provided.’’. 
(b) PRODUCTS PREVIOUSLY APPROVED UNDER SEC-
TION 505.— 
(1) REQUIREMENT TO FOLLOW SECTION 351.— 
Except as provided in paragraph (2), an application 
for a biological product shall be submitted under 
section 351 of the Public Health Service Act (42 
U.S.C. 262) (as amended by this Act). 
(2) EXCEPTION.—An application for a biologi-
cal product may be submitted under section 505 of 
the Federal Food, Drug, and Cosmetic Act (21 
U.S.C. 355) if— 
(A) such biological product is in a product 
class for which a biological product in such 
product class is the subject of an application 
approved under such section 505 not later than 
the date of enactment of this Act; and 
VerDate Aug 31 2005 
23:13 Mar 14, 2008
Jkt 069200
PO 00000
Frm 00026
Fmt 6652
Sfmt 6201
E:\BILLS\H5629.IH
H5629
rwilkins on PROD1PC63 with BILLS
(B) such application— 
(i) has been submitted to the Sec-
retary of Health and Human Services (re-
ferred to in this Act as the ‘‘Secretary’’) 
before the date of enactment of this Act; 
or 
(ii) is submitted to the Secretary not 
later than the date that is 10 years after 
the date of enactment of this Act. 
(3) LIMITATION.—Notwithstanding paragraph 
(2), an application for a biological product may not 
be submitted under section 505 of the Federal Food, 
Drug, and Cosmetic Act (21 U.S.C. 355) if there is 
another biological product approved under sub-
section (a) of section 351 of the Public Health Serv-
ice Act that could be a reference product with re-
spect to such application (within the meaning of 
such section 351) if such application were submitted 
under subsection (k) of such section 351. 
(4) DEEMED APPROVED UNDER SECTION 351.— 
An approved application for a biological product 
under section 505 of the Federal Food, Drug, and 
Cosmetic Act (21 U.S.C. 355) shall be deemed to be 
a license for the biological product under such sec-
VerDate Aug 31 2005 
23:13 Mar 14, 2008
Jkt 069200
PO 00000
Frm 00027
Fmt 6652
Sfmt 6201
E:\BILLS\H5629.IH
H5629
rwilkins on PROD1PC63 with BILLS
tion 351 on the date that is 10 years after the date 
of enactment of this Act. 
(5) DEFINITIONS.—For purposes of this sub-
section, the term ‘‘biological product’’ has the mean-
ing given such term under section 351 of the Public 
Health Service Act (42 U.S.C. 262) (as amended by 
this Act). 
SEC. 102. FEES RELATING TO BIOSIMILAR BIOLOGICAL 
PRODUCTS. 
Subparagraph (B) of section 735(1) of the Federal 
Food, Drug, and Cosmetic Act (21 U.S.C. 379g(1)) is 
amended by inserting ‘‘, including licensure of a biological 
product under section 351(k) of such Act’’ before the pe-
riod at the end. 
TITLE II—AMENDMENTS TO 
PATENT ACT 
SEC. 201. AMENDMENTS TO CERTAIN PATENT PROVISIONS. 
Section 271(e)(2) of title 35, United States Code is 
amended— 
(1) in subparagraph (A), by striking ‘‘or’’ after 
‘‘patent’’; 
(2) in subparagraph (B), by adding ‘‘or’’ after 
the comma at the end; and 
(3) by inserting the following after subpara-
graph (B): 
VerDate Aug 31 2005 
23:13 Mar 14, 2008
Jkt 069200
PO 00000
Frm 00028
Fmt 6652
Sfmt 6201
E:\BILLS\H5629.IH
H5629
rwilkins on PROD1PC63 with BILLS
‘‘(C) 
a 
statement 
under 
section 
351(l)(4)(D)(ii) of the Public Health Service 
Act,’’. 
Æ 
VerDate Aug 31 2005 
23:13 Mar 14, 2008
Jkt 069200
PO 00000
Frm 00029
Fmt 6652
Sfmt 6301
E:\BILLS\H5629.IH
H5629
rwilkins on PROD1PC63 with BILLS